Introduction the early phase of endocrine treatment and, if possible, with preservation of sexual function? The endocrine treatment of prostate cancer has changed rapidly in the last few years, a change made possible
The present author summarized the issue of the endocrine treatment of prostate cancer in the recent edition and necessary because of several important developments. Maximal androgen blockade (MAB), which has of Campbell's Urology [1] . That chapter was written in 1996 and many aspects are now outdated; the present occupied clinical research and resources for more than 10 years, has found a modest but clearly defined place review attempts to provide an update, to present a view on future research necessities and to anticipate clinical in the armamentarium of the endocrine management of metastatic prostate cancer. This development arrests developments. research potential, eliminates the need to use MAB as the 'gold standard' in metastatic and nonmetastatic
Maximal androgen blockade
disease and allows concentration on other relevant issues which have not been resolved, but which are of great MAB as a concept of treatment for prostate cancer is the simultaneous complete elimination or blockade of testicuimportance for the further development of the field. Such unresolved issues are the question of early vs delayed lar and adrenal androgens. In the literature, the synonyms complete androgen withdrawal, complete treatment, the value of adjuvant endocrine treatment, the evaluation of intermittent treatment, the possibility androgen blockade and total androgen blockade are used. The concept was first suggested by investigators of using very early endocrine treatment, aspects related to endocrine prevention, and the possibility of preserving from Italy and Germany in the 1960s and 1970s. The first randomized controlled study which tested MAB was quality of life, especially as it is related to sexual performance for at least some period.
the EORTC Genitourinary (GU) Group protocol 30805. This protocol was developed in 1979 and compared Another important aspect is not related to treatment, but to the disease. Endocrine treatment is bound to MAB achieved by castration plus cyproterone acetate (CPA) 150 mg/day to castration as a standard treatment, change because prostate cancer is diagnosed much earlier in life and with more favourable disease characterand to DES 1 mg in the third arm; 335 patients with metastatic disease were recruited. The final analysis [2] istics. Prostate cancer is more frequently treated by potentially curative means, but up to 30-40% of such showed no diCerences in time to progression and overall survival among the three treatment arms. In 1983, patients may escape such treatment and will eventually require early or delayed endocrine treatment. The durbased on experimental findings, Labrie et al.
[3] began to popularize the concept on the basis of a very small ation of endocrine treatment in patients who present with signs of biochemical progression after radiotherapy phase II study. Subsequently, many randomized comparative studies using various forms of MAB have been or radical prostatectomy likely to be very much longer than ever experienced before. How can we cope with carried out in the hope that MAB would significantly delay the progression to endocrine independence of this situation without imposing unacceptable side-eCects, which are related to such long durations of endocrine prostate cancer, and eventually prolong survival. Among more than 20 studies that address the issue, there were treatment? Which aspects of endocrine treatment need to be studied to provide future forms of endocrine two major protocols that seemed to fulfil these hopes, and to establish MAB as the standard treatment for management that are adapted to individual clinical situations, the need to prevent long-term side-eCects, e.g. metastatic prostate cancer [4, 5] . However, methodological problems around the largest of these studies, protocol osteoporosis, anaemia, and muscle wasting, the necessity 0036 of the South West Oncology Group (SWOG)/ included the individual data of 5710 patients, of whom 3283 had died. Another description of the meta-analysis, Intergroup [4] cast doubt on the validity of these data early on, mainly because the LHRH agonist in the control which is in many respects complementary, was given by Dalesio et al. [8] . Unfortunately, the data from three arm was used without antiandrogen protection in the initial phase of treatment, and diCerences in time to suitable trials could not be obtained. The endpoint of the analysis was the 5-year overall survival; separate analyprogression suggested an eCect of 'flare' in the control arm. The SWOG/Intergroup decided subsequently to ses for each treatment regimen were also carried out, and a common analysis of all trials together. Of all carry out another study and to replace the LHRH arm by castration, as had been done in the similar protocol patients, 13% had nonmetastatic disease; a separate analysis of those with metastatic disease with and withof the EORTC GU Group [5] . The results of this latter protocol (SWOG/Intergroup Study 105) together with out M0 cases did not alter the final results. While there were diCerences in 5-year survival, mainly related to the the results of a comprehensive meta-analysis have been decisive in judging the true value of MAB. The data use of three diCerent antiandrogens (flutamide, nilutamide and CPA), in none of these subgroup analyses was resulting from these two studies will now be reviewed.
there a significant improvement in 5-year survival; Fig. 1 . shows the survival estimates for all 5710 patients. The meta-analysis
There was an advantage for MAB at 5 years of 3.5%, which was not statistically significant. This metaWhy choose a meta-analysis, when a randomized study should be the most valid way of testing treatment analysis is currently being updated; the total number of patients is now #7500, with #5200 deaths. principles? Apparently this is not so; if only small or no diCerences exist between treatment regimens, a very large sample is necessary. Clinical trials, even if randomized, usually do not have the necessary power. In this situation, there is a some chance that even valid trials with the same methodology can lead to variable results. The chance of finding a positive or negative result in a situation where in fact no diCerence exists is estimated to be #10%. This error can be avoided by a meta-analysis. Another reason to use meta-analyses is the possibility of avoiding publication bias and the bias resulting from not considering papers written in languages that are diBcult to access. This has been called the 'Tower of Babel' bias. Publication bias results from the reluctance of study groups, authors and publishers to present and accept negative results for publication. A meta-analysis or overview analysis must include all studies, including those that are unpublished. A metaanalysis must access the original data, as the use of published data alone is unacceptable. Because a metaanalysis often has to disregard details which are addressed in individual trials, such as important prognostic factors, the meta-analysis has been blamed for 'comparing apples and pears'. However, these pitfalls can be avoided by running multiple analyses in which patients are separated according to such factors. Another prerequisite for conducting a meta-analysis is that all trials conducted before a fixed date are included. The relative value of large randomized trials and meta-analysis has recently been discussed in depth by LeLorier et al. [6] .
Almost all trials using MAB have been included in a meta-analysis conducted by the Prostate Cancer Trialists Cooperative Group (PCTCG) [7] . This study included 22 which were initiated before December 1989. The analysis Considering the negative outcome of the studies that progression to hormone-independence and death from prostate cancer. If a decrease of PSA to <4.0 ng/mL have been added, it cannot be expected that there will be a larger diCerence in favour of MAB. However, was considered as a response, there was a significant advantage in the proportion of responses in favour of considering the increase in power, a diCerence of #3% may be statistically significant. The question will then the flutamide group (OF 80%, OP 68%, P=0.001). Clearly, this is not reflected in an advantage for the main be; should every patient with metastatic prostate cancer receive MAB, to produce a 3.5% advantage in 5-year endpoints of the trial. In this trial, PSA cannot be considered a surrogate endpoint. survival? Side-eCects, other therapeutic options, quality of life and cost will have to be considered in this context.
Reviewing the results of this largest single, wellcontrolled study together with the results of the metaanalysis, MAB is clearly not the treatment of choice for SWOG/Intergroup study 105 metastatic prostate cancer. It is possible that subgroups of patients would benefit from MAB, but these have not Recently, the results of this important protocol have been published [9] ; the study compares bilateral orchibeen properly identified. dectomy combined with flutamide vs placebo in patients with metastatic prostate cancer. The study is doubleRemaining indications for MAB blind for flutamide and placebo; 1387 patients were randomized between 15 December 1989 and If endocrine treatment by the use of an LHRH agonist is chosen, an antiandrogen should be added before the 15 September 1994. At the time of the analysis presented in 1997, the study was mature. The main endpoints are initiation of, or at the time of treatment to suppress disease 'flare'. Many trials that have compared MAB to survival and progression-free survival. A stratification by minimal disease (MD, 283 patients) and extensive more standard forms of endocrine treatment, and which have studied response as a study endpoint, have found disease (ED, 1088 patients) was carried out to confirm diCerences found in the earlier protocol [4] , in which that tumour markers become normal and symptoms of prostate cancer resolve more quickly, and often signifi-MAB seemed to be more eCective in patients with MD. The follow-up was 3 monthly and the results of protocol cantly more frequently (as in SWOG/Int 105), than with castration or the use of LHRH agonists. The use of MAB, 105, as they were presented in 1997, are reproduced in Table 1 . Of 1387 patients, 1371 were eligible; more at least temporarily, should be considered in patients who initially present with symptoms related to prostate than half of all patients have progressed and/or died. Toxicity favoured the placebo group, with significant cancer (e.g. bone pain, neurological symptoms, impaired micturition). A faster and more pronounced response diCerences for diarrhoea (P<0.001) and anaemia (P= 0.046) and a trend toward more favourable liver funccan be expected; however, this may not be expected to translate into an advantage in time to progression tion. The results are given for the treatment groups of orchidectomy plus flutamide (OF) and orchidectomy plus and/or survival. The role of second-line endocrine treatment with placebo (OP); similar numbers of patients were eligible for evaluation. Also, the proportions of patients with MD antiandrogens needs to be further investigated; available information is old and poorly controlled. Further and ED were similar in the two treatment groups. There were no significant diCerences in median or overall research to identify subgroups that may benefit from MAB may be warranted. However, without repeating survival.
An important question in the further exploration of very large studies, this may prove to be impossible. endocrine treatment is whether PSA could be used as a surrogate marker. This would allow a shortcut in the trial design by avoiding the necessity of waiting for ; and (ii) should patients with lymph node metastases be treated immediately after diagnosis, or period of 3 years from the diagnosis of metastatic disease to death, one year was added to account for the earlier whenever metastatic progression occurs?
Recently, the scope of the problem has become much diagnosis of M+ disease during follow-up. A 4-year period from the diagnosis of M1 to death was included in all wider. Evidence for tumour progression is no longer based on an elevation of acid phosphatase, alkaline phosphatase, time estimates in Fig. 2 -II-IV. Fig. 2 -II, which relates to N+M0 disease, shows a drastically longer time from positive bone scans, metastases visible on X-rays and complaints of patients related to various types of prodiagnosis to metastatic progression. In a sample of 34 cases from a randomized prospective study of N+M0 gression, including local progression. Local progression after potentially curative management and metastatic cases (EORTC protocol 30846) the median time to progression in 34 treated patients was 6 years [12]; T3 progression of any type are heralded long before metastases can be diagnosed by a rise in the serum level of PSA.
prostate cancer seems to be quite similar to N+M0 disease, but only a few observations on the natural history The availability of PSA as a marker of 'biochemical progression' has advanced by some years the possibility are available. From the placebo groups to which delayed treatment was applied within the Veterans Administrative of identifying tumour progression and, if this is considered an indication for treatment, also increased the time during
Cooperative Urological Group (VACURG) studies 1 and 2
[13], median times of almost 7 years (study 1) and 4 years which endocrine treatment might be applied. Figure 2 shows an attempt to quantify this changing situation.
(study 2) can be extrapolated for progression from stage 3 to stage 4. The mean time to progression to metastatic Estimates of median times to clinical progression and disease of nonmetastatic patients in the MRC study (MRC Prostate Cancer Working Party, [10]) was 27 months.
Adolfsson et al.
[14] found a median time to progression in T3 G1+2 disease of about 7 years. A 4-year period is inserted for progression to M+ disease in Fig. 2 -III, relating to T3 disease. These diCerences show how relative and inaccurate such historical comparisons may be. The assumption made for N+and T3 disease, that the time from metastatic progression to death is comparable to cases presenting with metastases at diagnosis, may also be very inaccurate. Within a follow-up scheme, metastatic disease may be detected much earlier and therefore this period may be longer. Obviously, the time of overall survival is also influenced by age at diagnosis. However, to make the point of this discussion, exact estimates are unnecessary. Figure 2 -IV is based on solid information and relates to men who presented with apparently locally confined disease (T2), who underwent radical prostatectomy, and subsequently suCered progression. Median times from radical prostatectomy to PSA progression, and [17, 18] (after watchful waiting) disease specific. VI, T1a [19, 20, 21] .
value was 6 years [16] . These data show that locally confined disease, even if it progresses after radical prostacourse, or even to prostate cancer just diagnosed in locally confined stages? There are currently no answers tectomy, on average has a slow course and may be associated with a median duration of untreated and to these questions. However, the clinician who wishes to apply early treatment in very early stages of the treated natural history of about 12-13 years. Similar projections can be made using the data of Johansson et al.
disease needs to be aware of the natural course for each stage, as it is roughly indicated in Fig. 2 . Are we doing [17] and Adolfsson et al. [18] , but have the disadvantage of excluding grade 3 disease. Figure 2 -VI depicts the more harm than good if we treat patients for periods of Á10 years by endocrine means? It will be shown below natural course of truly focal disease (T1a), as it is identified as an incidental finding in benign prostatic specimens that the expected side-eCects will have to be matched by a significant prolongation of life for this to be acceptable. removed for symptomatic BPH. Only one report gives a median time to progression, of #13.5 years for A1 disease Meanwhile, the available information arising from randomized studies of early vs delayed endocrine treatment in 143 patients [19] . This median time can be extrapolated from Kaplan-Meier projections. Epstein et al. [20] reported remain to be reviewed. 16% progression with 96 months of follow-up, and Blute et al.
[21] 26.6% with 10.2 years of follow-up. It is
The VACURG studies estimated that the median time to clinical progression may be 13-15 years. The lead-time, i.e. the time by
The first study that addressed this question, albeit indirectly, was VACURG study 1, a randomized study of which the diagnosis is advanced by the use of early detection regimens, e.g. achievable using PSA-driven patients with locally extensive and metastatic prostate cancer, comparing 5 mg DES with castration, to screening, may be 4-10 years [22, 23] . In future, with increasing screening for prostate cancer, this amount of castration+5 mg DES, and to placebo [13, 26] . In this study, when progression to symptomatic metastatic distime may have to be added to the clinical course of many patients. This also means that there will be a shift from ease occurred, 44% of the patients randomized to placebo transferred to active endocrine treatment. Because there more extensive to less extensive disease at the time of diagnosis. This trend is confirmed by many recent studies was no diCerence in overall survival, comparing the placebo group with the active treatment groups, one of in the USA, and on the European continent [24, 25] .
How does all this relate to the question of early vs the conclusions of the study was that it did not matter whether treatment was instituted early or later during delayed endocrine treatment? Obviously, if for example in Fig. 2 -IV, the situation of PSA progression after radical the clinical course. VACURG study 2, which included low dosages of DES (0.2 and 1.0 mg), was set up to prostatectomy (or radiotherapy), endocrine treatment is given at the time of PSA elevation, the duration of exclude the cardiovascular toxicity seen in study 1 with 5 mg DES. Study 2 was discontinued because again, in endocrine treatment will be drastically increased. This duration is unknown at present. However, the median the 5 mg DES arm of the study, there was an excess of cardiovascular death. With only 506 patients rantime to metastatic progression without endocrine treatment is 6-8 years. Endocrine treatment periods of domized (475 were randomized to each of the four treatment groups in study 1), the power of this study 10 years in this and similar situations must be anticipated. Also, the application of this treatment will increase was limited. However, the patients treated with 1 mg DES showed a significant advantage in overall survival as more patients will be diagnosed with locally confined disease in the future, and will receive potentially curative over the placebo group and the other DES groups. This study was extensively analysed and as a result the advice treatment. Obviously, the side-eCects of endocrine treatment over very long periods will diCer importantly from about early vs delayed endocrine treatment resulting from study 1 was revised. The final conclusion was that those that are experienced in patients who present with locally advanced or metastatic disease, because of the younger patients with poorly diCerentiated tumours should be treated immediately, and that older patients much longer duration of treatment. This issue will be dealt with later in this article.
and patients with low-grade disease (Gleason score 2-6) probably do not need early hormone therapy [13] . In this context, what is early endocrine treatment? Is it treatment given at the time of diagnosis of metastatic disease, of lymph node positive disease, at the time of
The MRC trial PSA progression, or at the time of diagnosis of any type of prostate cancer? If we examine the issue of early vs
The conclusions from VACURG Study 2 have not found widespread acceptance. However, patients and treating delayed endocrine treatment in metastatic disease, locally extensive disease, or in lymph node positive disease, are urologists are reluctant to see tumours progress with rising PSA levels and without treatment. It is probably the results obtained applicable to situations where signs of progression are detected much earlier in the clinical mainly for this reason that early endocrine treatment is used increasingly often. The only truly randomized study unavailable. Also, it is very unclear whether the preliminary information that is available can be applied to the addressing the issue has recently been published by the MRC Prostate Cancer Working Party Investigators Group situation of very early progression, such as a minimal rise in PSA level after radical prostatectomy or radio-[10] (subsequently referred to as the MRC study). The study was designed to compare the eCect of early endotherapy, or whether the question of early vs delayed treatment will find diCerent answers by disease stage. crine treatment vs delayed endocrine treatment in patients with locally extensive or asymptomatic meta-
The treating urologist and the patient have to be aware of the long duration of endocrine treatment, if it is static prostate cancer, which was previously untreated. A total of 934 patients were randomized, 469 to immediapplied early, and of the accumulation of side-eCects that may occur with prolonged treatment. ate and 465 to deferred treatment (503 M0, 261 M1 and 174 Mx). Of the patients who died, 67% did so from What are the potential benefits and pitfalls of early vs delayed endocrine treatment? Take the example of a prostate cancer. There was a significant diCerence in favour of immediate treatment for overall survival of all patient with an intact libido and who is sexually active in some way, not necessarily with intact erections; he is patients (P=0.02). There were larger and statistically significant diCerences for time to death from any cause 65 years old and has a life expectancy without prostate cancer of #15 years. He has a rising PSA level after in M0 patients, as well as time to death from prostate cancer in M0 and M1 patients; 203 patients died from radical prostatectomy or radiotherapy. What does early treatment oCer? As detailed above, the median time to prostate cancer in the immediate and 257 in the delayed treatment arm, a diCerence of 54 cancer deaths, which metastatic progression in this case is 6-8 years and depends on the original tumour characteristics. It is well explains all significant diCerences encountered, as time to death from causes other than prostate cancer did not known and understood that endocrine treatment prolongs time to progression. Treatment with a 5a-reductase diCer between the treatment groups. The authors report that of the 54 cases who died in the delayed treatment inhibitor in this situation will delay the rise of PSA and of progression by 9 months [27] . It has been shown that arm, 29 (54%) never received endocrine treatment. The participants in this protocol were encouraged to manage more aggressive endocrine treatment will then decrease the PSA level and will again produce a period of PSAtheir patients 'according to their clinical practice'; a follow-up form was requested once a year. Bone scans based remission of probably several years, say three. This means that a patient who chooses early endocrine were not available for many of the participants. If progressive disease had been diagnosed with a 3-monthly treatment in this situation is likely to be treated for 9-12 years until he experiences metastatic progression. follow-up and treated appropriately, how would that have changed the final outcome? Is it inevitable to miss If that occurs, there will be no eCective treatment in reserve. In the meantime, he has lost libido and potency, progression in some patients? Ongoing EORTC studies on the same issue do not confirm this possibility.
and has encountered several side-eCects, elaborated below. In the worst case, he has suCered a hip fracture or other spontaneous fracture due to osteoporosis, which What to do?
could have been avoided otherwise. At the time of metastatic progression, unfortunately no eCective theraOther studies, mainly at the level of the EORTC GU Group, are currently underway. Results based on at least peutic options are available and the patient will then probably succumb within a year. 1500 patients in two protocols comparing early vs delayed treatment in lymph node-positive disease (EORTC What does delayed treatment oCer? The patient will have to live with the knowledge of a rising PSA level. If 30846), and in M0 cases with all local stages (EORTC protocol 30891) will be ready for final evaluation in the this keeps him awake at night, he is symptomatic and must be treated. In my experience of this situation, near future. Preliminary evaluation of these protocols has shown that only very few patients will ever progress explanations such as mentioning the well-known median times until metastatic disease occurs help the patients to and die from prostate cancer without receiving endocrine treatment. Also, the serious complications (spontaneous understand better what they may and may not expect. Also, to indicate that metastatic disease is rarely seen fractures, paraplegia, etc.) described in the MRC study are rare in these studies. Clearly, a patient with locally with PSA values of <100-200 ng/mL gives them an idea of how relative a PSA increase from, e.g. 2 to advanced or metastatic prostate cancer, in whom endocrine treatment is delayed, has to have the opportunity 4 ng/mL, may be. Meanwhile, during watchful waiting the patient can enjoy a normal libido and sexual life. He and must be ready to undergo regular follow-up examinations, probably at 3-monthly intervals.
is not at risk from the side-eCects of endocrine treatment and, if progression finally occurs, an eCective treatment In the author's view, conclusive data which dictate either the use of early or delayed treatment are currently will be in reserve.
In the author's view, both options should be explained to patients and they should be given a choice, as long as clear advantages for disease-specific and overall survival have not been shown. The EORTC GU Group protocol 30846, of which the randomization scheme is shown in Fig. 3 , has been in progress since 1984. About 290 patients have been included. Despite very large diCerences in time to progression in the two arms, and despite two reviews by the Data Monitoring Committee that functions as an ethical supervisory body of this study, the protocol has not been discontinued because apparently there have been no diCerences in survival; the situation around protocol 30891 is similar.
Side-eVects of endocrine treatment it is thought that after castration this eCect is immediate (green) or cyproterone acetate (red) in a randomized study (EORTC and it seems to be related to the elimination of testicular protocol 30892).
androgens. However, in a classic paper, Ellis et al. [28] found that after castration, treatment with oestrogens as described above. Daniell [30] described an important or the combination of both regimens, 16 of 38 previously increase in osteoporosis and osteoporotic fractures after potent patients remained potent for prolonged periods. orchidectomy in comparison with an age-matched popuThis finding is confirmed by recent data relating to the lation of men with intact testicular function, over a use of antiandrogen monotherapy [29] . These data are period of 9 years; the results are depicted in Fig. 5 . The derived from EORTC GU Group protocol 30892, a ranoccurrence of a decrease in bone mineral density, which domized study of patients with metastatic prostate cancer leads to osteoporotic fractures if critical limits are passed, treated by either flutamide or CPA monotherapy.
is clearly related to the decrease of circulating androgens. The pale appearance of many patients under endocrine [29] . The important message is that the loss of sexual treatment is caused by significant anaemia that results function under monotherapy with either a pure or a from low androgen levels. This has been quantified steroidal antiandrogen is a slow process. It does not recently by Strum et al. [33] . A probable mechanism seem to be true that sexual function is preserved with and the immediate recovery of red blood cell counts with flutamide monotherapy, as has been claimed previously. androgen substitution have been described by Weber However, 10-20% of patients remain potent over obseret al.
[34]. vation times of 2-6 years with both antiandrogens; the mechanism is unexplained. These observations open possibilities for new strategies in the use of antiandrogens.
Other side-eCects of endocrine treatment are also timedependent and may not become relevant with the short treatment periods usually necessary for the management of metastatic disease. However, they may be very relevant for prolonged periods of endocrine treatment, such Low circulating testosterone levels also lead to muscuReferences lar atrophy; this may be related to mechanisms described underway to further explore the value of this type of (b) was shown beyond doubt to be more eCective if
